Connect with us

Technology

Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs

Published

2 years ago

on

BOSTON, Feb. 28, 2024 /PRNewswire/ — Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie’s infrastructure and software for training large-scale AI foundation models and four of Reverie’s key AI team members will join Ginkgo. The acquisition is intended to strengthen Ginkgo’s AI/ML-driven discovery services offering and to accelerate Ginkgo’s work to build next-generation biological foundation models.

Anna Marie Wagner, SVP, Head of Corporate Development and Head of AI of Ginkgo Bioworks: “The Reverie Labs team has built an impressive platform and architecture for computationally-driven biological discovery and validation, and it’s going to be very exciting to be able to use the tools they’ve developed across the wide, diverse range of discovery challenges our customers face. It has been a joy to work with this team throughout the transaction, and I’m looking forward to working with the Reverie team to accelerate the development of multimodal foundation models at Ginkgo.”

The Reverie team joining Ginkgo as a part of this transaction (including Reverie’s CTO, Ankit Gupta, who will be joining Ginkgo as Head of AI/ML Advancement) will support both the onboarding of Reverie’s technology into Ginkgo’s growing AI/ML infrastructure and also support the future development and application of AI/ML-based techniques to engineer biology. Ginkgo will incorporate Reverie’s models, software, and workflows to advance its infrastructure for AI/ML-driven experimental design. Reverie’s generative AI platform for chemistry will also be added into Ginkgo’s capabilities to support small molecule programs.

Jonah Kallenbach, CEO and co-founder of Reverie Labs: “Our team at Reverie has made great strides using machine learning modeling to improve human wellbeing, and I am eager to marry our technology with Ginkgo’s repository of data, enabling Ginkgo to build some of the world’s best AI models to engineer biology and chemistry. Ginkgo is a perfect home for the technology that Ankit, the Reverie team, and I have built over the last six years, and I am very excited to see the impact it will have in the short and long term.”

Ankit Gupta, CTO and co-founder of Reverie Labs: “Joining forces with Ginkgo Bioworks is an incredibly exciting next step in our mission of building and deploying machine learning models to solve impactful problems in biology. Working with Ginkgo’s incredible biopharma and academic partners, we’re excited to advance the entire industry with a positive feedback loop between generative AI and biology at Foundry scale. We’re especially motivated by the impact our combined team can have on human health and biosecurity worldwide.”

Ginkgo’s existing AI/ML-driven efforts include Owl, its tool for AI-guided design. Owl integrates with a full range of computational tools, selected by Ginkgo’s enzyme engineering team and proven out over dozens of projects. Last year, Ginkgo also announced a strategic partnership with Google Cloud to build a generative AI platform for engineering biology and for biosecurity. Additionally, Ginkgo has partnered with Merck to improve its biologic manufacturing, with Pfizer to advance the discovery and development of novel RNA molecules across priority research areas, and with Boehringer Ingelheim to accelerate discovery and development of novel therapeutic molecules to address hard-to-treat diseases.

To learn more about Ginkgo Biopharmaceutical Services, please visit https://www.ginkgobioworks.com/offerings/biopharmaceutical/

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the acquisition and Ginkgo’s cell programming platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-reverie-labs-platform-enhancing-ai-driven-drug-discovery-capabilities-for-customer-programs-302073641.html

SOURCE Ginkgo Bioworks

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

World IP Day 2026: PitchMark launches Ideas.Exchange to help creators safeguard and license ideas in the age of AI

Published

4 hours ago

on

April 26, 2026

By

SINGAPORE, April 26, 2026 /PRNewswire/ — To mark World IP Day 2026, PitchMark® today launched Ideas.Exchange, a first‑of‑its‑kind platform designed to help creators assert intellectual property rights, license ideas, and formalise creative conversations in an increasingly AI‑driven economy.

Unveiled at Safeguard Your IP in the Age of AI, a media briefing hosted by CNBC’s Sri Jegarajah, the platform responds to growing concern that ideas are routinely used, reused or absorbed without attribution, consent or compensation—often with limited legal or commercial recourse.

“AI has amplified both the reach and the risk for creators,” said Mark Laudi, Managing Partner of PitchMark LLP. “Ideas.Exchange gives creators a way to protect themselves while still participating confidently in the market for ideas.”

At its core, the platform focuses on three interventions for creators:

Asserting IP rights by establishing proof of authorship and precedenceLicensing ideas without giving them away for freeFormalising conversations so pitches and evaluations are governed rather than informal

Ideas.Exchange is powered by three proprietary resources developed by PitchMark. These include a blockchain‑driven clearing house where ideas and creative works can be listed and licensed; smart contracts that automate usage terms and reduce disputes; and an IP Governance Certification Program designed to signal responsible handling of ideas, particularly in enterprise and AI contexts.

The result, PitchMark says, is three concrete outcomes: deterrence of idea theft, new ways to monetise ideas through structured licensing and price discovery, and a more level playing field that allows creators to pitch to clients and platforms on equal terms.

The launch comes amid renewed scrutiny of how intellectual property is treated in the AI era. While idea theft is rarely reported, its impact is significant. Beyond visible financial losses, organisations and creators often absorb hidden costs through talent attrition, innovation suppression and abandoned market opportunities.

“Most idea theft occurs informally and never reaches the courts,” said Prof David Llewelyn, Professor Emeritus of Law at Singapore Management University. “Introducing governance, traceability and standards is a meaningful step toward addressing that gap.”

Spokespeople including Prof Llewelyn, technology lawyer Bryan Ghows, and Mark Laudi are available for interview.

About PitchMark

PitchMark® deters idea theft and enables creatives to get paid by providing a trusted way to share and license ideas with prospects and clients.

 

View original content:https://www.prnewswire.com/apac/news-releases/world-ip-day-2026-pitchmark-launches-ideasexchange-to-help-creators-safeguard-and-license-ideas-in-the-age-of-ai-302753571.html

SOURCE PitchMark

Continue Reading

Technology

SK hynix receives 2026 IEEE Corporate Innovation Award for Driving AI Computing Expansion with HBM

Published

4 hours ago

on

April 26, 2026

By

SK hynix honored at the 2026 IEEE Awards for leading AI technology innovation with HBM Contributed to the global AI computing ecosystem via stable mass production across all HBM generationsCompany committed to becoming a premier leader in AI innovation through collaboration with global customers and partners

SEOUL, South Korea, April 25, 2026 /PRNewswire/ — SK hynix Inc. (or “the company”, www.skhynix.com) announced today that it received the Corporate Innovation Award at the ‘2026 IEEE1 Honors Ceremony’ held in New York on the 24th (local time).

IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Established more than a century ago, the IEEE Awards Program recognizes individuals and teams whose innovations have advanced technology and improved the human condition.

The IEEE Corporation Innovation Award, part of the Recognitions category, has been presented since 1986 to companies that have significantly contributed to the advancement of industry and society through innovative technology. This marks the first time SK hynix has received this honor.

SK hynix attributed the honor to its contribution to the global AI computing ecosystem by ensuring the stable mass production of all High Bandwidth Memory (HBM) generations. Looking ahead, the company aims to solidify its position as a trusted partner in the global AI market by providing memory solutions that are critical to overcoming the performance limitations of AI platforms.

The recognition highlights SK hynix’s achievements in driving the expansion of AI computing through HBM innovation and application. Central to this success was the company’s ability to preemptively offer innovative HBM solutions and respond timely to customer demands in the global AI market.

Industry observers also credit this achievement to the strategic direction of SK Group Chairman Chey Tae-won, who has long emphasized securing long-term technological competitiveness. Under his leadership, the company has consistently expanded its AI infrastructure partnerships with global Big Tech firms in the United States.

Ahn Hyun, President and Chief Development Officer (CDO), attended the ceremony as the company representative to accept the award.

“It is an honor to receive this award on behalf of our employees, who have tirelessly challenged the limits of technology,” said Ahn. “By collaborating closely with our global customers and partners, we will stay ahead in creating the value the market demands and continue to be a premier company leading AI innovation.”

About SK hynix Inc.
SK hynix Inc., headquartered in Korea, is the world’s top-tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

About IEEE
IEEE is the world’s largest technical professional organization and a public charity dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org.

View original content:https://www.prnewswire.com/news-releases/sk-hynix-receives-2026-ieee-corporate-innovation-award-for-driving-ai-computing-expansion-with-hbm-302753615.html

SOURCE SK hynix Inc.

Continue Reading

Technology

NCL (Formerly Natural Cure Labs) Unveils New Brand Identity, Reinforcing Its Position as a Leading Monolaurin Supplement Company

Published

7 hours ago

on

April 25, 2026

By

Natural Cure Labs, one of the most recognized monolaurin supplement brands in the United States, is officially transitioning to NCL – the same company, same formulations, and same science-backed standards, under a streamlined name.

ST. PETERSBURG, Fla., April 25, 2026 /PRNewswire-PRWeb/ — Natural Cure Labs, one of the most recognized monolaurin supplement brands in the United States, is officially transitioning to NCL. The company, founded in 2015, is adopting a streamlined brand identity while maintaining the same formulations, manufacturing standards, team, and commitment to quality its customers have trusted for more than a decade.

“NCL represents the quality, transparency, and innovation that our community expects from us. As we enter this new chapter, our commitment to our customers and our standards remains as strong as ever.”

NCL stands for Natural Cure Labs. The name change reflects how customers and the team already refer to the company. Over the past 10+ years, “NCL” has become the natural shorthand for Natural Cure Labs – and this transition formalizes that identity. This is a name change and visual evolution only. Ownership, leadership, formulations, and values remain unchanged.

Same Mission, Sharper Identity

This transition is not a departure from who the company is – it is a natural progression. The values that have guided NCL from the very beginning remain unchanged: clean-label quality, third-party testing, science-backed formulations, and an unwavering commitment to transparency. What is changing is how the company presents itself. In the months ahead, this rebrand will be accompanied by further updates across the brand experience – from visual identity and packaging to how NCL shows up across every channel and platform. Each of these changes will reflect the same standard of excellence customers have come to expect.

What is changing is how the company presents itself. In the months ahead, this rebrand will be accompanied by further updates across the brand experience – from visual identity and packaging to how NCL shows up across every channel and platform. Each of these changes will reflect the same standard of excellence customers have come to expect.

More Than 10 Years of Trust

This evolution comes at a time of significant momentum. Since 2015, NCL has grown from a small startup into an award-winning wellness brand available nationwide through Amazon, Walmart, Target+, TikTok Shop, eBay, and other major marketplaces. Along the way, the company has reached milestones that reflect the trust its community has placed in it:

200,000+ customers served worldwide35+ million capsules sold7,000+ verified customer reviewsRecognition in the 2025 Inc. 5000 list of fastest-growing private companiesMultiple Stevie Awards from the American Business AwardsNamed a 2025 and 2026 Gator100 HonoreeThree-time Global 100 winner for Best Health & Wellness Nutrition Manufacturer

“This rebrand isn’t about changing who we are – it’s about evolving how we present ourselves to match the brand our customers already know and trust,” said Damon Sununtnasuk, Founder & CEO.

What This Means for Customers

For existing customers, nothing changes about the products they know and trust. The same formulations, manufacturing facilities, quality controls, and customer support team remain in place. Products sold as Natural Cure Labs and products sold as NCL are from the same company. Customers can continue to find NCL products on the company’s website and through Amazon, Walmart, Target+, Kroger, eBay, and other major marketplaces.

NCL is grateful for every customer who has been part of this journey and is excited for what is to come.

Media Contact

NCL (Natural Cure Labs), NCL (Natural Cure Labs), 1 8003036214, press@naturalcurelabs.com, https://www.naturalcurelabs.com/

View original content to download multimedia:https://www.prweb.com/releases/ncl-formerly-natural-cure-labs-unveils-new-brand-identity-reinforcing-its-position-as-a-leading-monolaurin-supplement-company-302753477.html

SOURCE NCL (Natural Cure Labs)

Continue Reading

Trending